COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study [PDF]
, 2022 Background: With the surge of new SARS-CoV-2 variants, countries have begun offering COVID-19 vaccine booster doses to high-risk groups and, more recently, to the adult population in general. However, uncertainty remains over how long primary vaccination
Capdevila J +10 more
core +1 more source
Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?
Journal of Pharmaceutical Policy and Practice, 2022 The Joint Committee on Vaccination and Immunisation (JCVI) in UK has recently advised that COVID vaccines in 5–11-year-old children is non-essential. This has created an outrage among some healthcare professionals who believed a mandatory vaccination ...
Hamid A. Merchant
doaj +1 more source
Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine
Cam & Sakura Medical Journal, 2023 Although thromboembolism after ChAdOx1 vaccine has been extensively reported, this association was rarely reported after vaccination with BNT162b2. We present the case of an otherwise healthy patient who developed concomitant acute limb ischemia and ...
Ahmet Can Topçu +3 more
doaj +1 more source
Acute myocarditis following administration of BNT162b2 vaccine
IDCases, 2021 The wide use of vaccines was linked with rare but serious complications in adults, causing a global concern. Here, we describe a young male patient, who presented with acute myocarditis, three days after the second dose of BNT162b2 vaccine.
Mhd Baraa Habib +4 more
openaire +3 more sources
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Expert Review of Vaccines, 2023 Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein.
Shanti Pather +3 more
doaj +1 more source
Safety and efficacy of RNA vaccines: State of the art
Медицинская иммунология, 2021 This review describes principles of action and the method of delivery of mRNA molecules into cells, as well as some of developed RNA vaccines and the results obtained in their study, though they have not been authorized for use yet.
A. V. Blagov +3 more
doaj +1 more source
Antibody responses after SARS-CoV-2 infection and vaccination in the UK general population [PDF]
, 2023 Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic since its first identification in December 2019.
Wei, Jia
core +2 more sources
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
Human Vaccines & Immunotherapeutics, 2023 This open-labeled non-inferiority trial evaluated immunogenicity and reactogenicity of heterologous and homologous COVID-19 vaccination schedules in pregnant Thai women.
Chenchit Chayachinda +16 more
doaj +1 more source
Branch Retinal Vein Occlusion after Messenger RNA-Based COVID-19 Vaccine
Case Reports in Ophthalmology, 2022 Two days after the second dose of the messenger RNA-based COVID-19 vaccine (BNT162b2), a healthy 38-year-old man developed branch retinal vein occlusion (BRVO) in his left eye (OS).
Kazunobu Sugihara +2 more
doaj +1 more source
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases [PDF]
, 2022 Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in immunogenicity and examining the effects of immunomodulatory treatments may support COVID-19 vaccination ...
Andrey, Diego O +15 more
core +1 more source